This trial is active, not recruiting.

Conditions hepatitis c, chronic, disease progression, liver cirrhosis
Sponsor Beijing YouAn Hospital
Start date July 2010
End date June 2011
Trial size 133 participants
Trial identifier NCT02011932, BJYAH-2011-045


The purpose of this study is to determine the progression of chronic hepatitis C patients infected by paid plasma donation,and explore the possible pathogenic mechanisms of disease progression in chronic hepatitis C.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Fibrosis progression rate
time frame: 20 years
The incidence of cirrhosis
time frame: 20 years
Risk factors for the occurrence of cirrhosis
time frame: 20 years

Secondary Outcomes

The incidence of hepatocellular carcinoma
time frame: 20 years
Number of participants with chronic hepatitis C-related complications
time frame: 20 years

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - All these patients had a definite history of regular plasma donations with repeated blood cell re-transfusions. - The Hepatitis C Virus antibody was positive. - All patients did not receive interferon therapy before being recruited. Exclusion Criteria: - Patients with evidences for other forms of liver diseases. - The coinfection with hepatitis B virus or other virus.

Additional Information

Official title Observational Study of Disease Progression and Risk Factors in Chronic Hepatitis C Caused by Plasma Donation
Principal investigator Zhongping Duan, Ph.D.,M.D.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by Beijing YouAn Hospital.